Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

norUrsodeoxycholic acid

Generic Name: norUrsodeoxycholic acid

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₃₈O_₄

CAS Number: 99697-24-2

Unique Ingredient Identifier: 8A5G600D9V

Overview

norUrsodeoxycholic acid is under investigation in clinical trial NCT03872921 (Norursodeoxycholic Acid vs Placebo in PSC).

Background

norUrsodeoxycholic acid is under investigation in clinical trial NCT03872921 (Norursodeoxycholic Acid vs Placebo in PSC).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

Phase 3

Not yet recruiting

Posted: 2025/03/20

Sponsor:Dr. Falk Pharma GmbH

ID:NCT06886360

Norursodeoxycholic Acid vs. Placebo in NASH

Phase 2

Recruiting

Posted: 2021/10/19

Sponsor:Dr. Falk Pharma GmbH

ID:NCT05083390

norUrsodeoxycholic Acid vs Placebo in PSC

Phase 3

Active, not recruiting

Posted: 2019/03/13

Sponsor:Dr. Falk Pharma GmbH

ID:NCT03872921

Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis

Phase 2

Completed

Posted: 2012/12/24

Sponsor:Dr. Falk Pharma GmbH

ID:NCT01755507

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Breakthrough in Primary Sclerosing Cholangitis: Dr. Falk Pharma's Norucholic Acid Shows Positive Phase 3 Results

21 days ago

Dr. Falk Pharma's pivotal Phase 3 trial of norucholic acid (NCA) demonstrated statistically significant superiority over placebo in treating primary sclerosing cholangitis, a rare liver disease with no currently approved treatments.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy